Methotrexate-Paclitaxel-Epirubicin-Carboplatin (M-TEC) Combination Chemotherapy in Patients with Advanced Bladder Cancer: An Open Label Phase II Study

References

• Otto T, Bex A, Krege S, Walz PH, Rubben H. Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (MI). A clinical phase II study. Cancer 1987; 80: 465–470.
   Google Scholar
• Sternberg CN, Yagoda A, Scher HI, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for ad-vanced transitional cell carcinoma of the urothelium. J Urol 1988; 139: 461–469.
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Dexeus FH, Chong C, et al. Cisplatin, cyclophosphamide and doxorubicin chemotherapy in unre-sectable urothelial tumors: the M.D. Anderson experience. J Urol 1989; 141: 33–37.
   Google Scholar
• Yagoda A. Chemotherapy of metastatic bladder cancer. Cancer 1980; 45: 1879–1888.
   PubMed Web of Science ®Google Scholar
• Loehrer PJ, Einhom LH, EIson PH, et al. A random-ized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; 10: 1066–1073.
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Samuels ML, Ogden SL, Dexeus FH, Chong CD. Cyclophosphamide, doxorubicin and cisplatin for patients with locally advanced uro-thelial tumors with or with-out nodal metastases. J Urol 1985; 134: 460–464.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985; 133: 403–407.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Wullink M, Oosterhof CON, de Mulder P. Toxicity and results of MVAC (methotrexate, vinblastine, adri-amycin and cisplatin) chemotherapy in advanced urothelial carcinoma. Eur Urol 1997; 131: 414–419.
   Google Scholar
• Harker WC, Meyers FJ, Freiha FS, et al. for the North-ern California Oncology Group Study. Cisplatin, methotrexate and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. J Clin Oncol 1985; 13: 1463-1470.
   Google Scholar
• Skarlos DV, Aravantinos G, Linardou H, et al. for the Hellenic Co-operative Oncology Group Study: Chemotherapy with methotrexate, vinblastine, epirubicin and carboplatin (Carbo-MVE) in transitional cell urothelial cancer. Eur Urol 1997; 31: 420–427.
   PubMed Web of Science ®Google Scholar
• McGuire WP, Rowinsky E, Rosenheim NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273–279.
   PubMed Web of Science ®Google Scholar
• Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 1797–1805.
   Google Scholar
• Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 384–388.
   PubMedGoogle Scholar
• Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium. J Clin Oncol 1994; 12: 2264–2270.
   PubMed Web of Science ®Google Scholar
• Pycha A, Grbovic M, Posch B, et al. Paclitaxel and car-boplatin in patients with metastatic transitional cell cancer of the urinary track. Urology 1999; 53: 511–515.
   Google Scholar
• Tsavaris N, Polyzos A, Kosmas C, Giannikos L, Gogas J. A feasibility study of one hour paclitaxel infusion in solid tumors. Cancer Chemother Pharmacol 1997; 40: 353–357.
   PubMed Web of Science ®Google Scholar
• Tsavaris N, Kosmas C. Risk of severe acute hypersensi-tivity reactions after rapid (less than 1 hour) paclitaxel infusion. Cancer Chemother Pharmacol 1998; 42: 509–511.
   PubMed Web of Science ®Google Scholar
• Calvert AH, Newell DR, Gumbell LA. Carboplatin dosage: prospective evaluation of a simple formula on renal function. J Clin Oncol 1989; 7: 1748–1756.
   PubMed Web of Science ®Google Scholar
• Miller A, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–217.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Non parametric estimation for incomplete observations J Am Stat Assoc 1958; 53: 457–481.
   Web of Science ®Google Scholar
• Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing CISCA to MVAC chemothe-rapy in advanced metastatic urothelial tumors. J Clin Oncol 1990; 8: 1050–1055.
   PubMed Web of Science ®Google Scholar
• Saxman S, Propert K, Einhorn L, et al. Long term fol-low-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial cancer: a cooperative group study. J Clin Oncol 1997; 15: 2564–2569.
   PubMed Web of Science ®Google Scholar
• Sousa-Escandon A, Vazquez S, Quintero-Aldana G, et al. Neo-adjuvant treatment of infiltrating transitional-cell carci-noma of the bladder with paclitaxel and cisplatin: a phase II trial. Int J Urol 2002; 9: 162–166.
   PubMed Web of Science ®Google Scholar
• Vaughn DJ. Paclitaxel and carboplatin in bladder can-cer: recent developments. Eur J Cancer 2000; 36: 7–12 (Suppl 2).
   PubMedGoogle Scholar
• Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002; 20: 937–940.
   PubMed Web of Science ®Google Scholar
• Vaughn DJ, Manola J, Dreicer R, See W, Levitt R, Wilding G. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer 2002; 95: 1022-1027.
   Google Scholar
• Bamias A, Aravantinos G, Deliveliotis C, et al., and Hellenic Cooperative Oncology Group. Docetaxel and cis-platin with granulocyte colony-stimulating factor (G-CSE) ver-sus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004; 22: 220–228.
   PubMed Web of Science ®Google Scholar
• Edelman MJ, Meyers FJ, Miller TR, Williams SG, Candour-Edwards R, deVere White RW. Phase VII study of paclitaxel, carboplatin, and methotrexate in advanced transi-tional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation. Urology 2000; 55: 521–525.
   Google Scholar
• Mulatero C, McClaren BR, Mason M, Oliver RT, Gallagher CJ. Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma. Br J Cancer 2000; 83: 1612–1616.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Cos J, Cleries R, et al. Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest 2002; 20: 673–685.
   PubMed Web of Science ®Google Scholar
• Li J, Juliar B, Yiannoutsos C, et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 2005; 23: 1185–1191.
   PubMed Web of Science ®Google Scholar
• Hussain M, Vaishampayan U, Du W, Redman B, Smith DC. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001; 19: 2527–2533.
   PubMed Web of Science ®Google Scholar
• Hoshi S, Ohyama C, Ono K, et al. Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin com-bined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report. Int J Clin Oncol 2004; 9: 125–129.
   PubMedGoogle Scholar
• Dreicer R, Manola J, Roth BJ, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 2004; 100: 1639–1645.
   PubMed Web of Science ®Google Scholar